Made under Section 5 (c) of the Tanzania Food, Drugs and Cosmetics Act, 2003 | Second Edition
Guías para programas nacionales y otros interesados directos
Série de bulletins techniques
Tuberculose et co-infection par le VIH | 1 - 3
Accessed November 2017
Morbidity and Mortality Weekly Report
Recommendations and Reports: July 7, 2006 / Vol. 55 / No. RR-9
Regional Tuberculosis Program, Pan American Health Organization (PAHO/WHO)
La Ceiba – Honduras, 20 - 22 de febrero, 2013
Trabajemos por prisiones y países libres de tuberculosis
PeerJ PrePrints , http://dx.doi.org/10.7287/peerj.preprints.579v1 2 Nov 2014
Disability Inclusion | Published by Child Development & Rights and Sustainable Health on behalf of World Vision International.
Background document to the 2018 joint statement by WHO, UNFPA, UNICEF, ICM, ICN, FIGO and IPA: definition of skilled health personnel providing care during childbirth
The goal of this Global Action Plan is to articulate synergistic actions that will be required to prevent HIVDR from undermining efforts to achieve global targets on health and HIV, and to provide the most effective treatment to all people living with HIV including adults, key populations, pregnant ...and breastfeeding women, children and adolescents. The Global Action Plan has five strategic objectives: 1) prevention and response; 2) monitoring and surveillance; 3) research and innovation; 4) laboratory capacity; and 5) governance and enabling mechanisms.
more
The HIV drug resistance report 2021 summarizes findings from 38 countries that had finalized the surveys by the time of this report and shared data with WHO.
Pretreatment HIVDR to non-nucleoside reverse-transcriptase inhibitors (NNRTI) can affect more than 10% of adults starting therapy and is fo...und up to 3 times more often in people who had previous exposure to antiretroviral drugs. In addition, nearly half of infants newly diagnosed with HIV has HIVDR to NNRTI before initiating treatment.The high levels of observed NNRTI pretreatment HIVDR among emphasize the need to fast-track the transition to WHO-recommended dolutegravir-based ART.
more